Exhibit 10.30

 

[g238141kqi001.jpg]

 

SUPPLY AGREEMENT

 

BETWEEN

 

POLYPLUS-TRANSFECTION SA, a company organized under the laws of France
(“Polyplus”), having its place of business at Bioparc, Boulevard Sébastien
Brant, 67401 Illkirch (France) hereinafter referred to as “SELLER” or “Seller”

 

AND

 

SENESCO TECHNOLOGIES, Inc. a Delaware corporation, having its registered office
at 303 George Street, Suite 420, New Brunswick, NJ 08901, USA, hereinafter
referred to as “BUYER” or “Buyer” (each being referred to individually as a
Party and collectively as the Parties)

 

WHEREAS

 

Polyplus is a biotechnology company dedicated to the development, manufacturing
and marketing of transfection reagents. These chemical agents make it possible
for DNA, interfering ribonucleic acids (siRNA) or proteins to enter into cells.

 

In particular, the firm is owner and licensed of intellectual property rights
related to transfection reagents including Polyethylenimine (PEI).

 

Polyplus has also developed methods for manufacturing PEI and derivatives. The
process is derived from know-how arising out of POLYPLUS’ research.

 

in vivo-jetPEI™, which is a Polyplus product, is manufactured by a Polyplus
subcontractor in its capacity as a GMP maker (hereinafter: “Product Maker”)
acting under Polyplus’s instructions and is marketed by Polyplus. in
vivo-jetPEI™ can be used for research or preclinical phases, as well as for
clinical trials.

 

BUYER is interested in using in vivo-jetPEI™ for human clinical trials and is
desirous to be regularly supplied with in vivo-jetPEI™.

 

Given the very high distinctiveness of this product, the Parties agree on the
establishing of a long-lasting contractual relationship to make easier the
regularity and the quality of the supply of this product.

 

1

--------------------------------------------------------------------------------

 

NOW, THEREFORE, IT HAS BEEN AGREED AS FOLLOWS

 

ARTICLE 1: DEFINITIONS

 

For the purposes of this Agreement, the following terms used herein with an
initial capital letter shall have the following respecting meanings, and shall
be applicable both to the singular and plural forms:

 

1.1                           “Affiliate” shall mean, as applied to a Party, any
corporation or other business entity, which controls, is controlled by or is
under common control with such Party. For the purposes of this definition, the
term “control” shall mean direct or indirect ownership of fifty percent (50%) or
more of the securities or other ownership interests representing the equity,
voting stock, general partnership or membership interest of such entity, or the
power to direct or cause the direction of the management and policies of an
entity (other than a natural person), whether through the majority ownership of
voting capital stock, by contract or otherwise

 

1.2                           “Business days” the part of a day from 9 am to 5
pm Monday through Friday, except for French or US state holidays

 

1.3                           “Clinical Trials” shall mean any investigation in
human subjects intended to discover or verify the clinical, pharmacokinetic
(study of the processes of bodily absorption, distribution, metabolism, and
excretion of compounds and medicines), and/or other pharmacodynamic (study of
interactions between drugs and living structures) effects of (an)
investigational drug(s), and/or to identify any adverse reactions to (an)
investigational drug(s), with the object of ascertaining its(their) safety
and/or efficacy.

 

For the sake of clarity, it is hereby stated that, according to international
standards, clinical trials are usually broken down into the following three
steps:

 

· Phase I studies, corresponding to the first time the drug is tested in (a
limited number of) humans, and which are primarily concerned with the drug’s
safety, with the purpose of determining how the experimental drug is absorbed,
metabolized, and excreted in humans. Additionally, these studies seek to
determine what types of side effects occur as the dosage of the drug is
increased. Any beneficial effects of the drug are also noted.

 

· Phase II studies, generally conducted on a random and blinded basis on several
hundred patients, and whose aim is (i) to test the experimental drug in the
patients that have the disease or condition that the drug is expected to
improve/cure, (ii) to evaluate the effectiveness of the drug, and (iii) to
determine the correct dosage, that is, the most effective dosage with the least
number of side effects (dose-ranging studies). In general, the purpose of Phase
II studies is to provide the sponsor

 

2

--------------------------------------------------------------------------------

 

and the competent regulatory agency with comparative information about the
relative safety of the experimental drug, the proper dosage needed to treat the
condition, and the drug’s effectiveness.

 

· Phase III studies, where the experimental drug is tested in several hundred to
several thousand patients with the disease/condition of interest, with this
large-scale testing seeking to provide the sponsor as well as the competent
regulatory agency with a more thorough understanding of the drug’s
effectiveness, benefits/risks, and range/severity of possible adverse side
effects.

 

1.4                           “Confidential Information” shall mean any
technical or business information furnished by one Party (the “Disclosing
Party”) to the other Party (the “Receiving Party”) in connection with this
Agreement, regardless of whether such information is specifically designated as
confidential and regardless of whether such information is in written, oral,
electronic or other form. Such Confidential Information may include, without
limitation, the trade secrets, know-how, inventions, formulations, compositions,
synthesis operating procedures, protocols, technical data or specifications,
testing methods, business or financial information, research and development
activities, product and marketing plans, and customer and supplier information.
The Confidential Information shall not include applicable information which the
Receiving Party can demonstrate:

 

· was in the public domain prior to the time of its disclosure under this
Agreement;

 

· entered the public domain after the time of its disclosure under this
Agreement through means other than an unauthorized disclosure resulting from an
act or omission by the Receiving Party;

 

· was independently developed or discovered by the Receiving Party prior to the
time of its disclosure under this Agreement, as demonstrated by contemporaneous
written evidence;

 

· is or was disclosed to the Receiving Party at any time, whether prior to or
after the time of its disclosure under this Agreement, by a third party having
no fiduciary relationship with the Disclosing Party and having no obligation of
confidentiality with respect to such Confidential Information or;

 

· is required to be disclosed so as to comply with applicable laws or
regulations, or with a court or administrative order, provided that the
Disclosing Party receives, to the extent practicable, prior written notice of
such disclosure and the opportunity to assess the need to disclose and/or limit
the scope of disclosure, and that the Receiving Party takes all reasonable and
lawful actions to obtain confidential treatment for such disclosure and, if
possible, to minimize the extent of such disclosure.

 

Confidential Information shall not be deemed to be in the public domain merely
because it is embraced by more general information in the public domain, or
merely because individual items of Confidential Information are in the public
domain, without a notice or suggestion associated with such individual items to
be combined in the manner suggested by the Disclosing Party.

 

1.5                           “Field” shall mean research applications, in
particular, the in-vivo use in clinical trials, for phases I, II and III of
those Clinical Trials.

 

3

--------------------------------------------------------------------------------

 

1.6                           “Product” shall mean the in vivo-jetPEI™ GMP,
manufactured by or on behalf of Seller, according to the applicable
Specifications, or any product whose function is accurately equivalent, provided
such product received the prior written approval of the Buyer.

 

1.7                           “Specifications” shall mean the applicable
specifications as defined in quotations made by Seller in view of orders from
the Buyer.

 

ARTICLE 2: SUBJECT MATTER OF THE CONTRACT

 

2.1                           Subject to the terms and conditions of this
agreement, Buyer agrees to purchase from Seller exclusively the Products needed
for use in the Field and Seller agrees to supply Buyer with its requirements of
the Product as detailed in quotations which will be made between the Parties
from time to time.

 

Seller agrees to supply Buyer with the Product in compliance with the
Specifications and amounts as detailed in the quotations which will be made
between the Parties from time to time.

 

2.2                           The Product will be supplied as Drug Substance
under lyophilised form. The filling step is not included in the present
agreement.

 

2.3                           During the initial term of this agreement
according to subparagraph 9.1 below, and after successful supply by Seller of a
first batch of Products meeting Specifications, Buyer shall purchase all its
requirements for such Product within the Field from Seller and undertakes not to
purchase any product whose structure and formula will be identical to the one of
the Product with any third parties.

 

ARTICLE 3: FORECASTS AND ORDERS

 

3.1                           General: The Product will be produced by Seller or
on behalf of Seller, on order from the Buyer and will be delivered for each
batch of Product within the time required for correct production.

 

3.2                           Forecasts: In order to ensure proper application
of § 3.1 hereinabove, Buyer shall provide Seller with written forecasts of its
requirements of Product for use in the Field regarding Phase I of Clinical
Trials, broken down by quarter for the ensuing 12 (twelve) months. Such
forecasts shall be updated every quarter. Buyer shall provide Seller with
written forecasts of its Product requirements for use in the Field under Phase
II and Phase III of the Clinical Trials 8 months before the beginning

 

4

--------------------------------------------------------------------------------

 

of each of that new phases, including in case of overlapping or coupling of one
phase with another (“Fast Track”).

 

3.3                           Orders: Buyer shall place its firm orders at least
6 (six) months before the requested delivery date. Buyer shall place firm orders
for the quantity most recently estimated for the Clinical Trial, it being
specified that such estimate must be based on a document prepared using
objective criteria for the purpose of conducting said Clinical Trials. The
Parties shall agree from time to time on the information to be included in the
order form.

 

3.4                           Acceptance of orders: Subject to the producing
capacity of the Product Maker, Seller shall fill Buyer’s orders for Product for
use in the Field to the extent they do not exceed Buyer’s forecast for such
Clinical Trial. Seller shall use its reasonable efforts to fill any portion of
the orders exceeding the forecast to the extent they do not exceed one hundred
twenty percent (120%) of this forecast . Notwithstanding the reservations
expressed in the foregoing, Seller shall have a period of ten Business days in
which to confirm its acceptance of each order.

 

ARTICLE 4: QUALITY

 

4.1                           Seller warrants that all Product sold to Buyer
hereunder shall be produced in accordance with the latest revision of the EC
Guide to Good Manufacturing Practices, shall be of good and merchantable quality
and comply with the applicable Specifications. It is understood that, even if a
batch of Product meets all Specifications at the time of delivery, its stability
will be affected by the passing of time. The expiration date will be determined
after the complete stability study performed on the first batch of Product.
Moreover, the stability of the Product is much shorter when the Product is mixed
to constitute a compound. Buyer shall be completely responsible for storage and
preserving conditions of the Product after delivery. Likewise, (i) Buyer shall
remain responsible for storage conditions of the Product employed by
investigators, inspectors, clinical research coordinators and other persons
involved in clinical studies, and undertakes to inform them about Product
features and requirements as to storage and preservation, and (ii) Seller does
not warrant the stability of the Product after delivery.

 

4.2                           Promptly after receipt of any shipment of Product,
Buyer shall verify the quantity and visually inspect the quality of the Product.
No claim for visible defective quality or shortage in quantity of any individual
shipment of Product shall be valid unless made in writing within ten
(10) Business days from the date of delivery of Product, together with
certificates of analysis, except in the event of latent defects, in which case
such claims shall be made within ten (10) Business days from discovery of such
defect. Such written notice shall substantiate the non-conformity to
Specifications.

 

5

--------------------------------------------------------------------------------

 

4.3                           Seller shall promptly make up any shortfall and/or
replace all Product non-conforming to the Specifications, at no additional cost
to Buyer, as stated below.

 

4.4                           If a dispute arises concerning conformity of the
Product to Specifications or requirements as agreed to by the Parties, in whole
or in part, such dispute shall be referred to a reputable independent testing
organization recognized by the pharmaceutical industry, mutually agreed by the
Parties. The fees and expenses of such organization shall be borne by the losing
Party. The settlement of such dispute shall be limited to the loss or damage
arising directly from the non-conformity of the Product without prejudice to any
additional remedies that may be perused by the Parties.

 

ARTICLE 5: DELIVERY

 

5.1                           Seller shall deliver or have delivered by Product
Marker the Product to filling facilities as indicated by Buyer. The Product
shall be packaged in keeping with the nature of the Product in order to maintain
its qualities. Risk for the Product shall pass to Buyer at the time of delivery.

 

5.2                           Seller shall provide certificates of analysis for
the Product for each delivery at the time of such delivery.

 

ARTICLE 6: PRICE AND PAYMENT CONDITIONS

 

6.1                           Prices: The prices for the Product delivered in
batches depend on the quantities ordered by Buyer and shall be set forth in each
quotation. The prices are exclusive of any taxes and duties, such as sales,
export, import, value-added tax, excise duty, which shall be added as
applicable. Seller may require changes in the prices to reflect changes in
Specifications, batch size, packaging and process alterations where such changes
are made at the Buyer’s request or pursuant to an agreement entered into by the
Parties providing for the modification of the Specifications.

 

6.2                           Invoices: Seller shall issue an invoice for thirty
percent (30 %) of the nominal amount of each order upon acceptance. The balance,
plus or minus adjustments for the quantity actually delivered shall be invoiced
according to milestones payments to be defined between the Parties at the time
of the order, it being specified that in case the Parties fail to reach
agreement the balance shall be fully paid in the following condition: 30% within
4 months from the date of the order, 40% upon delivery. Buyer shall pay invoices
in Dollars within thirty (30) days from the date of the invoice by bank transfer
to the account indicated in the invoice. Any payments not made on or before the
due date shall accrue interest, from the tenth day following a written payment
reminder sent by Seller to Buyer until paid, at a rate equal to the EURIBOR in
effect on the date such payment first became due and payable.

 

6

--------------------------------------------------------------------------------

 

6.3                           Retention of title: to the extent permitted by
law, title to the Product shall remain with Seller until the price is paid in
full.

 

6.4                           Cancellation for non–payment: Should any payment
not be received within 60 days from the invoice date, this Agreement may be
cancelled eo ipso upon Seller’s request.

 

ARTICLE 7: PRODUCT LIABILITY

 

7.1                           Warranties: Seller warrants that:
(i) Product(s) sold to Buyer pursuant to this Agreement shall, at the date of
delivery, be free from defective material and workmanship, conform to the
Specifications, contain no hidden defects, satisfy current FDA requirements and
be in compliance with applicable EU legal and regulatory requirements as may be
amended from time to time; and (ii) Seller has requisite know-how, required
expertise, and experience regarding the Product.

 

For the sake of clarity it is again stated that Seller makes no warranty
regarding the stability of the Product after delivery. However, Seller
undertakes to provide its expertise after delivery and carry out the stability
study according to the Specifications upon Buyer’s request, as long as the
Product is in the same condition as it was at the time of delivery. It being
specified that should the stability study show that the Product has not kept the
stability it had at the time of the delivery, Seller shall not be obliged to
replace the Product and shall not incurred any liability.

 

SELLER MAKES NO OTHER WARRANTY, EXPRESS OR IMPLIED, CONCERNING THE PRODUCT, and,
in particular, makes no warranty regarding the effectiveness of the Product once
it has been mixed to constitute a compound.

 

7.2                           Seller’s indemnification and hold harmless
agreement for the benefit of Buyer: Seller shall defend, indemnify and hold
Buyer, its Affiliates and the officers, directors and employees of each harmless
from and against any and all claims, demands, loss, damage, liabilities,
settlement amounts, costs or expenses whatsoever (including reasonable
attorneys’ fees and costs) arising from any claim, action or proceeding made or
brought against such party by a third party as a result of (a) nonconformity of
the Product to the Specifications; or (b) Seller’s intentional act or grave
misconduct in performing its obligations herein; or (c) Seller’s breach of its
obligations as detailed herein. SELLER MAKES NO OTHER WARRANTY, EXPRESS OR
IMPLIED, CONCERNING THIS PROTECTION.

 

7.3                           Buyer’s indemnification and hold harmless
agreement for the benefit of Seller: Buyer shall defend, indemnify and hold
Seller, it’s Affiliates and the officers, directors and employees of each
harmless from and against any and all claims, demands, loss, damage,
liabilities, settlement amounts, costs or expenses whatsoever (including
reasonable attorneys’ fees and costs) arising from any claim, action or
proceeding made or brought against such party by a third party as a result of
(a) any damage caused by the use of the Product except a damage due to a defect
in the product caused, in

 

7

--------------------------------------------------------------------------------

 

whole or in part, from the manufacture of the Product, a default in the storage
of the Product prior to delivery in accordance with Article 5, or the
nonconformity of the Product to the Specifications, but including a defect of
the product with which or into which the Product will be incorporated, mixed or
associated or (b) Buyer’s failure to perform its obligations hereunder or
(c) the use of the Product outside the Field. BUYER MAKES NO OTHER WARRANTY,
EXPRESS OR IMPLIED, CONCERNING THIS PROTECTION.

 

7.4                           Limitations: The foregoing indemnification and
hold harmless undertakings shall be contingent on the observance of the
following additional terms and conditions:

 

(i) The party claiming indemnification shall have given the indemnifying party
prompt and timely notice of the facts and circumstances having given rise to
such claim and shall reasonably co-operate with, inform and assist the latter
party in this regard;

 

(ii) The indemnifying party shall have sole control and authority with respect
to the defence, settlement or compromise of the claim against the indemnified
party; provided, however, that the indemnifying party shall not agree to any
settlement which would materially and adversely affect the business of the other
party without the prior written consent of that party, which consent shall not
be unreasonably withheld.

 

7.5                           Insurance obligation: The Buyer, as sponsor of the
Clinical Trials, shall maintain in effect a policy or policies of insurance
providing protection against the risk of liability associated with any loss,
injury or damage arising from the performance of Clinical Trials, and it shall
provide the Seller with the relevant insurance policy upon Seller’s request.

 

ARTICLE 8: CONFIDENTIALITY

 

8.1                                 Confidentiality and non-use covenants: Each
Party shall and shall cause its employees, agents or servants engaged in the
performance of this Agreement to: (i) maintain all Confidential Information
received from the other Party in strict confidence; (ii) use all such
information solely for purposes of performing this Agreement; and
(iii) reproduce such information only to the extent necessary to perform this
Agreement, with all such reproductions being considered Confidential
Information. The terms and conditions hereof shall be considered Confidential
Information, unless both Parties agree in writing to disclose certain terms in
reply to a legitimate request by a third party.

 

8.2                                 Return of documents: Upon the termination of
this Agreement by either Party, the Receiving Party shall return to the
Disclosing Party all originals, copies, and summaries of documents, materials,
and other tangible manifestations of Confidential Information in the possession
or control of the Receiving Party, except for one copy, which may be kept in the

 

8

--------------------------------------------------------------------------------

 

Receiving Party’s legal archives and stored under secure conditions. The
obligations set forth hereunder shall remain in effect for a period of ten
(10) years after receipt of the Confidential Information by the Receiving Party.

 

ARTICLE 9: TERM AND TERMINATION

 

9.1                           Term: This Agreement shall enter into force on the
date of last signature hereof and shall have an initial term ending on the
eighth anniversary of the first Commercial Sale of the Product by Seller to
Buyer. It shall remain in force thereafter for consecutive one (1) year periods
except if terminated by either party, upon giving six (6) months written notice
prior to the initial or any renewal term.

 

9.2                           Survival:  Termination, expiration, cancellation
or abandonment of this Agreement through any means or for any reason, shall be
without prejudice to the rights and remedies of either party with respect to any
antecedent breach of any of the provisions of this Agreement. The provisions of
Sections 7, 8, 9, 10 and 12 hereof shall survive expiration or termination of
this Agreement.

 

9.3                           Termination for breach: Either Party may terminate
this Agreement on written notice to the other Party, with immediate effect, if
the other Party commits a material breach of any of its obligations essentially
but non limitatively stipulated in Article 2.3; Article 6.4; Article 7.3 and
Article 8.1 hereunder which is not cured within thirty (30) days of the other
Party’s written notice of the breach. Such right of termination shall be without
prejudice to any other remedy the non-defaulting party may have at law due to
the other party’s breach of its obligations hereunder.

 

9.4                           Termination for liquidation: This Agreement may be
immediately terminated by a Party if the other Party is dissolved or liquidated,
files or has filed against it a petition under any bankruptcy or insolvency law,
makes an assignment for the benefit of its creditors or has a receiver appointed
for all or substantially all of its property.

 

9.5                           Consequences of termination: Expiration or
termination of this Agreement in whole or in part shall not relieve the Parties
of any amounts of moneys or Product duly owing between them according to the
terms of this Agreement.

 

9

--------------------------------------------------------------------------------

 

ARTICLE 10: INTELLECTUAL PROPERTY RIGHTS

 

10.1                     Intangible Property : Buyer acknowledges that any and
all of Seller’s intellectual property rights including its know-how used or
embodied in or in connection with the Product and any parts thereof (hereafter:
Seller’s Background IP Rights) are and shall remain the sole property of Seller.
Seller acknowledges that any and all of Buyer’s intellectual property rights not
in connection with the product and any parts therof existing prior to the
present Agreement or developed later on are and shall remain the sole property
of Buyer.

 

10.2                     Improvements : In case Improvements (defined as “any
ameliorations that cannot be exploited without infringing Seller’s Background IP
Rights) to the Product or to its method of manufacture or use are generated in
the performance of the Agreement or of the Clinical Trials by either or both
parties, all rights on these Improvements shall belong to Seller which shall
have the sole right, and at its own discretion, to file patent applications in
its own name and at its costs. Buyer undertakes to keep Seller regularly
informed, once a year, of the Improvements it shall make and to sign any
documents that could be necessary in order for Seller to file patent
applications and to secure its ownership.

 

Any other improvements or inventions generated by Buyer in the performance of
the Clinical Trials will belong to Buyer.

 

10.3                     No warranty : Seller hereby declares that to the best
of its knowledge the Products do not infringe patents, trademarks or other
proprietary rights owned or controlled by any third party, and warrants that no
litigation or threatened litigation exist in connection with the use of such
third party proprietary rights as of the coming into force of this Agreement.

 

However, no representation is made by Seller, expressly or by implication, that
any Products sold to and used by Buyer will not infringe such third party
proprietary rights. Accordingly, Seller shall not be responsible, either
directly or as an indemnitor, to Buyer, for any consequence of any alleged,
purported or established infringement of said third party’s rights in connection
with or resulting from said use of Products, and Buyer shall indemnify and hold
harmless Seller with respect to any claims or actions of third parties related
thereto.

 

10.4                     If Buyer becomes aware of any infringement by third
parties of any of Seller’s Background IP Rights. Buyer shall give written notice
to Seller of such fact, it being understood and agreed that Seller alone shall
decide, at its sole discretion, whether, and if so, what measures shall be taken
as a result of any such infringement.

 

10

--------------------------------------------------------------------------------

 

ARTICLE 11: GENERAL PROVISIONS

 

11.1                     Force Majeure: The failure of either Party to perform
any of its obligations hereunder solely by reason of, acts of government -
particularly if at any time Seller or its Product Maker cease to be entitled for
any reason whatsoever to sell or manufacture the Product-, riots, wars, strikes,
natural disaster such as fire, storm and flood or other outside causes beyond
its control, shall not be deemed to be a breach of this Agreement; provided,
however, that the Party so prevented from complying herewith shall continue to
take all actions within its power to comply as fully as possible herewith. If
such prevention continues for a period of more than sixty (60) days, then either
Party may terminate this Agreement, effective upon written notice to the other
Party.

 

11.2                     Assignment: This Agreement and each and every covenant,
term and condition herein is binding upon and inures to the benefit of the
Parties hereto and their respective successors, and may not be assigned or
transferred by either Party to a third party.

 

11.3                     Headings: Headings are inserted for convenience only
and shall not affect the meaning or interpretation of this Agreement.

 

11.4                     Waiver: No waiver of any default hereunder by either
Party or any failure to enforce any rights hereunder shall be deemed to
constitute a waiver of any subsequent default with respect to the same or any
other provision hereof.

 

11.5                     Severability: Should any part of this Agreement be held
unenforceable or in conflict with the applicable laws or regulations of any
jurisdiction, the invalid or unenforceable part or provision shall be replaced
with a provision which accomplishes, to the extent possible, the original
business purpose of such part or provision in a valid and enforceable manner,
and the remainder of this agreement shall remain binding upon the Parties
hereto.

 

11.6                     Notices: All notices given by one Party to the other
shall he sent by registered air mail or fax to the other party’s address as
first set out hereinabove or to the latest address of such Party as shall have
been communicated to the other Party.

 

11.7                     Entire agreement: This Agreement constitutes the entire
Agreement between the parties and shall prevail over any other prior
understanding or terms (including Buyer’s general purchase conditions). Any
amendment or modification to this Agreement shall be valid only if made in
writing and signed by authorized representatives of the Parties.

 

ARTICLE 12: GOVERNING LAW – JURISDICTION

 

12.1.                  Governing Law: Without regard to choice of law provisions
and regardless of the place or places where the terms hereof are actually
performed, this Agreement shall be governed by,

 

11

--------------------------------------------------------------------------------

 

construed and enforced in accordance with the laws of France, excluding the
Vienna Convention on the International Sale of Goods dated 11 April 1980.

 

12.2.                  Jurisdiction: ANY DISPUTE ARISING IN CONNECTION WITH THE
VALIDITY, INTERPRETATION OR THE PERFORMANCE OF THIS AGREEMENT SHALL BE REFERRED
TO THE COURTS OF STRASBOURG, FRANCE.

 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed
by their duly authorized representatives on the day and date written below.

 

Made and executed in two (2) counterparts, which taken together constitute one
and the same instrument, with one copy of each counterpart having been submitted
to each party.

 

BUYER

SELLER

Senesco technologies, Inc.

Polyplus transfection

 

/s/ Richard Dondero

 

/s/ Joelle Bloch

 

Name: Richard Dondero

Name: Joelle Bloch

Title: Vice President

Title: President

Place:

Place:  Illkiorch

Date:

Date:  06/27/2008

 

12

--------------------------------------------------------------------------------